POSTS
MORE
Merck’s COVID Pill Reduces Hospitalization
Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study At the Interim Analysis,
